Skip to main content
< Back
About
About the conference
App
Organisers & Partners
Latest updates
Press room
Registration
Venue 22
About the venue
Rooms
Call for abstracts
Programme 22
Tracks 22
Speakers 22
Side events 22
Subscribe
days
hours
minutes
seconds
Structured session
Sessions
Wednesday, 23 November
10:50
Addressing substance use and substance use disorders in humanitarian settings: the role of evidence-based prevention, treatment and care
10:50
to
12:20
Insights zone 4 (I4)
Structured session
Current and future challenges associated with emerging cannabis markets
10:50
to
12:20
Main stage
Structured session
Emerging changes in Europe's cannabis situation: policy preparedness and responses to a dynamic situation
10:50
to
12:20
Knowledge market 4 (K4)
Structured session
Foetal Alcohol Syndrome: piloting best practices towards FAS/FASD prevention. Results from the FAR SEAS European project
10:50
to
12:20
Central square 1 (C1)
Structured session
Prescription opioids and overdose deaths
10:50
to
12:20
Knowledge market 1 (K1)
Structured session
Substance-induced psychosis: register-linkage research in Nordic countries
10:50
to
12:20
Knowledge market 2 (K2)
Structured session
13:20
Assessing the impact of laws and policies regulating illicit drugs on health and society: some insights
13:20
to
14:50
Knowledge market 4 (K4)
Structured session
Cultures of prevention: training the workforce
13:20
to
14:50
Main stage
Structured session
Global digital addiction interventions: adaptations to target audiences and effectiveness
13:20
to
14:50
Insights zone 2 (I2)
Structured session
Migration, substance use and interventions in Europe
13:20
to
14:50
Insights zone 4 (I4)
Structured session
Policies for regulating cannabis supply in Europe and the US: the need for appropriate monitoring and evaluation
13:20
to
14:50
Knowledge market 1 (K1)
Structured session
Precision Medicine and Novel Approaches to the Treatment Alcohol Use Disorder
13:20
to
14:50
Central square 1 (C1)
Structured session
Prevention and control of infectious diseases among people who inject drugs: New evidence within the updated guidance from the ECDC and the EMCDDA
13:20
to
14:50
Networking zone 3 (N3)
Structured session
Special at-risk populations and need for diversified interventions to prevent overdoses: insights from the US and Europe, on fentanyl, suicidal overdoses and deaths among teen-agers
13:20
to
14:50
Central square 4 (C4)
Structured session
The future for Digital Addictions Services. An update from the DigitAS-DADE Project
13:20
to
14:50
Central square 2 (C2)
Structured session
15:00
Convergence in behavioural addictions
15:00
to
16:30
Main stage
Structured session
Drug Early Warning Systems – the key to preparedness and response to new psychoactive substances
15:00
to
16:30
Central square 2 (C2)
Structured session
How prepared are monitoring systems to respond to rapidly changing drug markets in regions bordering the European Union?
15:00
to
16:30
Insights zone 4 (I4)
Structured session
Implementation of quality standards in drug demand reduction – where we are and where we are going?
15:00
to
16:30
Knowledge market 1 (K1)
Structured session
INDRA: dialogues for an international didactic repository for addictions
15:00
to
16:30
Insights zone 2 (I2)
Structured session
Substance use and mental health disorders in Europe: prevalence, models of care, and implementation in a challenging COVID-19 context
15:00
to
16:30
Knowledge market 2 (K2)
Structured session
Towards endemicity: A global perspective of the many variants of drug consumption rooms and service models in operation
15:00
to
16:30
Insights zone 3 (I3)
Structured session
16:50
Addiction and comorbidity over the lifespan: mechanisms and interventions
16:50
to
18:20
Central square 2 (C2)
Structured session
Assessment of drug policies in light of Sustainable Development Goals and human rights
16:50
to
18:20
Knowledge market 1 (K1)
Structured session
Driving under the influence of cannabis (DUIC)
16:50
to
18:20
Insights zone 3 (I3)
Structured session
Hepatitis C prevention and treatment among people who inject drugs: Global progress and future requirements
16:50
to
18:20
Knowledge market 3 (K3)
Structured session
Impact and lessons learned in implementing and sustaining Needs-Based Planning models for substance use and mental health services and systems
16:50
to
18:20
Knowledge market 2 (K2)
Structured session
Scanner - Understanding the dynamics and consequences of new psychoactive substances in a rapidly changing (online) drug market
16:50
to
18:20
Insights zone 4 (I4)
Structured session
Treatment options for drug users in prisons in Central Asia and Germany
16:50
to
18:20
Networking zone 1 (N1)
Structured session
Why we need evidence-based approaches for the universal measurement of cannabis: rationale and implications for public health, treatment and research
16:50
to
18:20
Main stage
Structured session
Thursday, 24 November
09:00
The Spanish Network on Research on Primary Attention on Addiction (RIAPAd): a new multilevel integrated model of responsible research on Addiction Disorders
09:00
to
10:30
Knowledge market 4 (K4)
Structured session
10:50
Cannabis use and purchase behaviours in Canada, United States, Australia, and New Zealand: Findings from the International Cannabis Policy Study
10:50
to
12:20
Knowledge market 1 (K1)
Structured session
Current international evidence on prevalence and perceptions of Heated Tobacco Products (HTPs)
10:50
to
12:20
Insights zone 4 (I4)
Structured session
From Harm to Risk Reduction: OKANA’s 360o approach in Athens
10:50
to
12:20
Knowledge market 4 (K4)
Structured session
How can we improve global coverage of interventions to reduce drug-related harms?
10:50
to
12:20
Main stage
Structured session
Studying illegal drugs in socially embedded markets
10:50
to
12:20
Central square 2 (C2)
Structured session
Successful systemic management for addiction challenges and all its side effects
10:50
to
12:20
Central square 4 (C4)
Structured session
13:20
Cannabis and tobacco co-use: A ‘joint’ challenge for research and practice
13:20
to
14:50
Knowledge market 1 (K1)
Structured session
Cannabis Social Clubs: current experiences and future directions
13:20
to
14:50
Knowledge market 4 (K4)
Structured session
Drug checking in supervised drug consumption room: rationale, methods and results
13:20
to
14:50
Central square 4 (C4)
Structured session
Environmental prevention: why do we need it now and how to advance it?
13:20
to
14:50
Insights zone 2 (I2)
Structured session
Methods and Problems with Estimating Prevalence of People Who Inject Drugs, studies and debate on how to get better and more consistent estimates in Europe and Rest of the World
13:20
to
14:50
Central square 2 (C2)
Structured session
The globalised illicit drug market
13:20
to
14:50
Main stage
Structured session
15:00
A global symposium on the renaissance and promise of psychedelics for mental and substance use disorder treatment
15:00
to
16:30
Main stage
Structured session
Drug deaths: A social, structural and systems analysis
15:00
to
16:30
Knowledge market 1 (K1)
Structured session
Implementing Methamphetamine Prevention Strategies into Action (IMPRESA)
15:00
to
16:30
Knowledge market 4 (K4)
Structured session
Insights into acute recreational drug and new psychoactive substance toxicity – an update from the Euro-DEN Plus Project
15:00
to
16:30
Central square 2 (C2)
Structured session
The future of surveys in the field of alcohol research: Lessons learned from a large-scale European survey (DEEP SEAS project)
15:00
to
16:30
Central square 1 (C1)
Structured session
The global gambling industry: Structures, tactics, and networks of impact
15:00
to
16:30
Insights zone 3 (I3)
Structured session
The implementation and evaluation of “safer supply” programs in Canada as a response to an ongoing overdose crisis
15:00
to
16:30
Insights zone 4 (I4)
Structured session
16:50
How to develop global surveys, guidelines, checklists and consensus statements in prevention and treatment of addiction: new innovations in the pandemic era
16:50
to
18:20
Insights zone 4 (I4)
Structured session
Opportunities and challenges for countries in transition to overcome barriers to evidence-based policies and interventions
16:50
to
18:20
Networking zone 2 (N2)
Structured session
Prison and drugs: exploring social determinants and pathways to drug problem and incarceration
16:50
to
18:20
Central square 1 (C1)
Structured session
Problem gambling: models and their ethical implications
16:50
to
18:20
Insights zone 3 (I3)
Structured session
Substance use, suicide and self-harm: epidemiology and prevention
16:50
to
18:20
Main stage
Structured session
Treatment for cannabis use disorder: an update focusing in cultural characteristics
16:50
to
18:20
Knowledge market 4 (K4)
Structured session
Unpacking the neurobiology of cannabis use disorders and cannabinoids: findings from neuroimaging and experimental studies across different ages and world regions
16:50
to
18:20
Knowledge market 2 (K2)
Structured session
18:30
On the path towards elimination of hepatitis C – Models of care to reach people who inject drugs for testing and treatment
18:30
to
19:30
Knowledge market 4 (K4)
Structured session
Friday, 25 November
10:50
EUFAS/EAR European Addiction Award
Alcohol - no ordinary commodity, alcohol policies and The Gut-Brain Axis in AUD
10:50
to
12:20
Main stage
Structured session
Associations of alcohol and substance use with mental health
10:50
to
12:20
Knowledge market 2 (K2)
Structured session
COVID-19-adapted addiction services and impact for service users
10:50
to
12:20
Insights zone 4 (I4)
Structured session
Gender differences and gender identities in drug use, addiction and interventions: why gender matters
10:50
to
12:20
Networking zone 3 (N3)
Structured session
Investigating adolescent substance use and risk behaviours in the Mediterranean region: where do we stand?
10:50
to
12:20
Networking zone 4 (N4)
Structured session
Portuguese Drug Policy Model. Achievements and challenges
10:50
to
12:20
Central square 2 (C2)
Structured session
13:20
Barriers in the implementation of harm reduction interventions in European prisons. From evidence to practice
13:20
to
14:50
Main stage
Structured session
Cross-domain prevention: Preventing substance use (disorders) and antisocial behaviour together, importance of intersectoral action in prevention
13:20
to
14:50
Insights zone 2 (I2)
Structured session
Navigating the future of supervised consumption research and intervention: European and North American experiences
13:20
to
14:50
Central square 2 (C2)
Structured session
New advances in alcohol clinical research: evidence from three large National Institute for Health Research-funded randomised controlled trials
13:20
to
14:50
Networking zone 3 (N3)
Structured session
Stress and Addiction: Updates on the Chicken or Egg question
13:20
to
14:50
Central square 4 (C4)
Structured session
The experience of persons in homeless situation with alcohol related problems regarding a pharmacological harm reduction initiative
13:20
to
14:50
Knowledge market 4 (K4)
Structured session